FUNDING$2.2B Upfront Acquisition
Ollin Biosciences Agrees To $2.2B J&J Sale | Up To $3.33B With Milestones
Johnson & Johnson agreed to acquire Ollin Biosciences for $2.2B upfront plus up to about $1.125B in milestones, adding OLN324, a bispecific eye drug it describes as Phase 3, as Blackstone funds $750M of its development.
DEEP DIVE